XML 35 R22.htm IDEA: XBRL DOCUMENT v3.10.0.1
Segment Information and Concentrations
9 Months Ended
Sep. 30, 2018
Segment Reporting [Abstract]  
Segment Information and Concentrations

NOTE 17. SEGMENT INFORMATION AND CONCENTRATIONS

 

The Company operates its business on the basis of a single reportable segment, which is the business of developing proprietary drug therapies and providing such therapies through sterile and non-sterile pharmaceutical compounding services. The Company’s chief operating decision-maker is the Chief Executive Officer, who evaluates the Company as a single operating segment.

 

The Company categorizes revenues by geographic area based on selling location. All operations are currently located in the U.S.; therefore, total revenues for 2018 and 2017 are attributed to the U.S. All long-lived assets at September 30, 2018 and December 31, 2017 are located in the U.S.

 

The Company sells its compounded formulations to a large number of customers. Less than 10% of the Company’s total pharmacy sales were derived from a single customer for the three and nine months ended September 30, 2018 and 2017.


The Company receives its active pharmaceutical ingredients from three main suppliers. These suppliers collectively accounted for 58% and 51% of active pharmaceutical ingredient purchases during the three and nine months ended September 30, 2018, respectively, and 72% and 70% during the three and nine months ended September 30, 2017, respectively.